No Point of No Return | Center for Cancer Research
Overturning a long-held dogma of how cells grow and divide, it turns out cells can reverse their decision to undergo mitosis, or cell division, later in the process than previously thought.
Overturning a long-held dogma of how cells grow and divide, it turns out cells can reverse their decision to undergo mitosis, or cell division, later in the process than previously thought.
In MONARCH 2, the addition of abemaciclib to fulvestrant significantly improved both progression-free survival (PFS) and overall survival (OS) in patients with HR+, HER2- advanced…
A chemotherapy-free regimen of trastuzumab plus pertuzumab generated a strong 3-year iDFS rate in patients with HER2-positive early breast cancer.
The Video Journal of Hematological Oncology (VJHemOnc) is a global, open-access video journal, dedicated to providing trusted and up-to-date medical information in order to improve…
The CT Screening Symposium is a 1-day, immersive, in-person event being featured at WCLC 2024 focused on lung cancer screening technologies and best practices. …
Here we summarize results from a phase II trial investigating the addition of nivolumab to CAR T-cell therapy in patients with progressive DLBCL, presented by…
The 15 inductees have been selected by their peers for their remarkable achievements in oncology research and clinical practice.
THERE was no better place to celebrate the 50th anniversary of the European Society for Blood and Marrow Transplantation (EBMT) than Glasgow, UK…
Nature Reviews Clinical Oncology – The question of whether chimeric antigen receptor (CAR) T cell therapies should be used in earlier lines (after 1–2 prior…
The ESMO Virtual Plenaries are freely available to all healthcare professionals working in Oncology.
Antonio Risitano, MD, PhD, AORN San Giuseppe Moscati Di Avellino, Avellino, Italy, presents encouraging data on the anti-complement agent iptacopan for treating paroxysmal nocturnal hemoglobinuria…